Wolwo Pharma
30035723.660.13% ( +0.03 )
Wolwo Pharma (300357)
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic disea...
- Open
- 23.45
- High
- 24.03
- Low
- 23.40
- Prev. Close
- 23.63
- Volume
- 71.48K
- Turnover
- 170.12M
- Avg Price
- 23.80
- Bid/Ask Ratio
- --
- Amplitude
- 2.67%
- 52wk High
- 35.59
- Volume Ratio
- 0.40
- Turnover Ratio
- 1.37%
Wolwo Pharma Analyst Rating
View MoreForecast & Rating
Jun 8, 2026Price forecast
¥38.2661.71%
Forecast & RatingBuy
2analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 13 hours ago
CEC Capital advises Zhongkexinyang on 100-million-yuan private financing round
- Zhitong · Oct 23, 2025 at 06:41 AM
Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%
- Zhitong · Oct 19, 2025 at 09:42 PM
A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit
- Zhitong · Sep 25, 2025 at 03:33 AM
Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solution
- Zhitong · Jul 22, 2025 at 04:42 AM
Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch
- Zhitong · Jun 5, 2025 at 04:33 AM
Zhongtai Securities: Maintain Wolwo Pharma "Buy" rating, steady revenue growth, core products continue to expand
